NCT05008055 - Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

August 22, 2023

Study Completion Date

October 25, 2024

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Capivasertib

Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.

Trial Locations (17)

3722

Research Site, Seoul

8035

Research Site, Barcelona

28040

Research Site, Madrid

28046

Research Site, Madrid

49241

Research Site, Busan

77030

Research Site, Houston

86021

Research Site, Poitiers

90095

Research Site, Los Angeles

91010

Research Site, Duarte

94805

Research Site, Villejuif

V8R 6V5

Research Site, Victoria

DK8200

Research Site, Aarhus N

06351

Research Site, Seoul

08003

Research Site, Badalona

CB2 0QQ

Research Site, Cambridge

M20 4BX

Research Site, Manchester

SM2 5PT

Research Site, Sutton